Fyn gene silencing reduces oligodendrocytes apoptosis through inhibiting ERK1/2 phosphorylation in epilepsy
Source abstract
Abstract
This study aimed to investigate the effect of Fyn gene silencing on the apoptosis of oligodendrocytes (OLs) in epileptic model in vitro and the involved mechanism. Primary oligodendrocyte pro-genitor cells (OPCs) were separated from rats and differentiated to OLs. Immunofluorescent labeling showed positive expression of A2B5 in OPCs and Olig2 in OLs, suggesting the successful separation of OPCs and OLs. Three Fyn siRNAs (si-Fyn) and Fyn siRNA negative control (NC) were transfected into OLs. Western blot showed that among three si-Fyn groups, si-Fyn3 caused the lowest Fyn expression, so si-Fyn3 was chosen for following experiment. Cells were divided into four groups: Control, Model, NC and si-Fyn. In the Model group, cells were cultured in Mg-free extracellular fluid for 3 h. The morphology of control cells was normal. However, the migration of neurons, the aggregation of cell bodies and the “grid-like” changes of neural networks were observed in the model cells. OLs apoptosis in various groups was assessed by flow cytometry. Expression of Fyn, ERK1/2 and phosphorylated ERK1/2 (p-ERK1/2) in OLs of various groups was evaluated by western blot. Compared with the Control group, the apoptotic rates, the Fyn expression and p-ERK1/2/ERK1/2 ratio in the Model and NC groups increased significantly (p < .05). However, the apoptotic rate, the Fyn expression and p-ERK1/2/ERK1/2 ratio in the si-Fyn group were remarkably smaller than those in the Model group (p < .05). In conclusion, Fyn gene silencing reduced the apoptosis of OLs through inhibiting the phosphorylation of ERK1/2 in epileptic model.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Neurogenesis and neuroplasticity mechanisms · Neuroscience and Neuropharmacology Research · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurology, The Second Affiliated Hospital of Nanchang University
References (24)
Show source-provided references
1. 10.1016/S1474-4422(15)00379-810.1016/S1474-4422(15)00379-8 ↗
2. 10.1086/31951610.1086/319516 ↗
3. 10.1111/epi.1367010.1111/epi.13670 ↗
4. 10.1001/jamaneurol.2013.585710.1001/jamaneurol.2013.5857 ↗
5. 10.1177/088307381453956010.1177/0883073814539560 ↗
6. 10.1002/glia.2268110.1002/glia.22681 ↗
7. 10.1007/s12035-017-0748-310.1007/s12035-017-0748-3 ↗
8. 10.1016/j.neuroscience.2017.03.03210.1016/j.neuroscience.2017.03.032 ↗
9. 10.1016/j.neuropharm.2017.11.04210.1016/j.neuropharm.2017.11.042 ↗
10. 10.1038/ncomms1483010.1038/ncomms14830 ↗
11. 10.1016/j.yebeh.2017.01.01510.1016/j.yebeh.2017.01.015 ↗
12. 10.1093/brain/aww29910.1093/brain/aww299 ↗
13. Hu X, Wang JY, Gu R, et al. The relationship between the occurrence of intractable epilepsy with glial cells and myelin sheath-an experimental study. Eur Rev Med Pharmacol Sci. 2016;20(21):4516–4524.
14. 10.1038/nm83710.1038/nm837 ↗
15. 10.1002/glia.2295010.1002/glia.22950 ↗
16. Lyu S, Han D, Li X, et al. Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the activated AMPK/mTOR signaling pathway. Oncol Lett. 2018;15:2085–2090.
17. Thompson SJ, Ashley MD, Stöhr S, et al. Suppression of TNF receptor-1 signaling in an in vitro model of epileptic tolerance. Int J Physiol Pathophysiol Pharmacol. 2011;3:120–132.
18. 10.1016/j.brainres.2017.11.01910.1016/j.brainres.2017.11.019 ↗
19. 10.1002/syn.2194510.1002/syn.21945 ↗
20. 10.1016/j.toxlet.2015.09.02110.1016/j.toxlet.2015.09.021 ↗
21. 10.3892/etm.2017.409310.3892/etm.2017.4093 ↗
22. 10.1007/s12035-018-1132-710.1007/s12035-018-1132-7 ↗
23. Pilar NM Elisabet GP Olmo Marisol MD. Compound inhibiting activation of the enzyme ERK1/2 for use in the treatment of neurogenerative illnesses. WO2011147999. 2016.
24. 10.1177/096032711665245810.1177/0960327116652458 ↗